Canada markets open in 3 hours 18 minutes

Marvel Biosciences Corp. (MRVL.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.1400-0.0150 (-9.68%)
At close: 02:38PM EDT
Full screen
Loading interactive chart...
  • Newsfile

    Marvel Biosciences Announces Positive Interim Results on Tau Phosphorylation with MB-204

    Calgary, Alberta--(Newsfile Corp. - March 25, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today reported promising interim results from its acute study on MB-204 conducted by Professor Emmanuel Planel of Laval University, a world expert on Tau pathology. Tau phosphorylation is a process where phosphates attach to a Tau protein in the brain. When Tau proteins become overly phosph

  • Newsfile

    Marvel Biosciences Announces Positive Interim Results for Autism Treatment with MB-204

    Calgary, Alberta--(Newsfile Corp. - March 12, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), today reported promising interim results from its study on MB-204, a new treatment for autism, conducted by the iBrain Institute in Tours, France. The study demonstrated that a single oral dose of MB-204 can restore social interaction behaviors to normal levels in autism model mice, with ..

  • Newsfile

    Marvel Biosciences Announces Testing MB-204 on Autism by French University

    Calgary, Alberta--(Newsfile Corp. - February 20, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce it has begun testing MB-204 in the Oprm1 mouse model of autism in collaboration with Dr. Julie Le Merrer and Dr. Jerome Becker at the iBrain Institute, Tours, France."We are going to test the effect of acute dosing of MB-204 in one ...